1269P

Preventing Infusion-related Reactions With Intravenous Amivantamab: Updated Results From SKIPPirr, a Phase 2 Study

Luis Paz-Ares[1,*], Alexander I Spira[2], Ji-Youn Han[3], Jin-Yuan Shih[4], Céline Mascaux[5], Upal Basu Roy[6], Jon Zugazagoitia[1], Yu Jung Kim[7], Chao-Hua Chiu[8], Sang-We Kim[9], Ernest Nadal[10], Ignacio Gil-Bazo[11], Parthiv Mahadevia[12], Bailey G Anderson[12], Karen Xia[13], George Wang[13], Joshua M Bauml[13], Marc Chioda[12], Jairo Simoes[12], Gilberto Lopes[14]

[1]Hospital Universitario 12 de Octubre, Madrid, Spain; [2]Virginia Cancer Specialists, Fairfax, VA, USA; [3]National Cancer Center, Goyang, Republic of Korea; [4]National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan; [5]University Hospital of Strasbourg, Nouvel Hopital Civil, Strasbourg, France; [6]LUNGevity Foundation, New York, NY, USA; [7]Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea; [8]Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan; [9]Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea; [10]Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain; [11]Instituto Valenciano de Oncología, Valencia, Spain; [12]Janssen Research & Development, Raritan, NJ, USA; [13]Janssen Research & Development, Spring House, PA, USA; [14]Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

*Presenting author

Key Takeaway

Prophylaxis with oral dexamethasone 8 mg BID effectively reduces intravenous (IV) amivantamab-related infusion-related reactions (IRRs), with a similar efficacy profile and no additional safety findings compared with historical IV data

Conclusions

- Prophylactic treatment with oral dexamethasone 8 mg BID resulted in reduced IRRs with IV amivantamab on Cycle (C) 1 Day (D) 1 compared with historical data
  - Most IRRs occurred on C1D1, and the majority were grade 1 or 2
- No new safety signals were observed with the addition of dexamethasone 8 mg BID
  - Patients experienced low rates of prophylaxis-related adverse events (AEs; 7%)
- Prophylaxis with dexamethasone 8 mg BID led to a similar treatment response compared with historical IV data[10,11]
- The duration of amivantamab infusion was numerically shorter with the dexamethasone 8 mg cohort compared with other cohorts, and patients also had a numerically shorter treatment room, chair, and active health care provider (HCP) time

Please scan QR code

Poster

Narrated poster video

https://www.congresshub.com/Oncology/ESMO2024/Amivantamab/Ares

Acknowledgments

We would like to thank the patients who participated in the study and their families and caregivers, the physicians and nurses who cared for patients and staff members who supported this clinical trial, and the staff members at the study sites and involved in data collection/analyses. Medical writing assistance was provided by Lumanity Communications Inc. and was funded by Janssen Global Services, LLC.

Disclosures

LP-A served in a consulting or advisory role for Roche, Merck Sharp & Dohme, Merck Serono, Bristol Myers Squibb, AstraZeneca, Lilly, Pfizer, PharmaMar, Bayer, Amgen, Janssen, GSK, Novartis, Takeda, Sanofi, Mirati Therapeutics, Genomica, Altum Sequencing, BeiGene, Daiichi Sankyo, Medscape, and PER; served as a member of the Board of Directors for STAb Therapeutics; received research funding from Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme, Bristol Myers Squibb, Janssen, Novartis, Roche, Sanofi, Amgen, TESARO, Asternes, Lilly, Takeda, Pfizer, and PharmaMar. **AIS** served in a consulting or advisory role for Array BioPharma, Incyte, Amgen, Novartis, AstraZeneca, Medtronene, Mirati Therapeutics, Gilthstone bio., Jacz Pharmaceuticals, Merck, Bristol Myers Squibb, Janssen, Mersana, Blueprint Medicines, Daiichi Sankyo, Regeneron, Lilly, Black Diamond Therapeutics, and Sanofi; served in a leadership role for Next Oncology; owns stock or has other ownership interests in Lilly; received payment or honoraria from CytomX Therapeutics, AstraZeneca, Merck, Takeda, Amgen, Janssen, Novartis, Bristol Myers Squibb, and Bayer; and received research funding from Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma, Medtronene, Novartis, Incyte, AbbVie, Ignyta, Takeda, MacroGenics, Cytomx Therapeutics, LAM Therapeutics, Aztex Pharmaceuticals, Bristol Myers Squibb, Loxo Oncology, Arch Therapeutics, Gilthstone bio, Pievaikon, Amgen, Daiichi Sankyo, ADC Therapeutics, Janssen, Mirati Therapeutics, Rubius Therapeutics, Synthekine, Mersana, Blueprint Medicines, Regeneron, Alkermes, Revolution Medicines, Medkine, Black Diamond Therapeutics, BioMed Oncology, NALO Therapeutics, Scorpion Therapeutics, and Anthrent Biopharma. **JY-H** served in a consulting or advisory role for Merck and AstraZeneca. **J-YS** received payment or honoraria from ACT Genomics, Amgen, Genconn Biotech, AstraZeneca, Roche, Bayer, Boehringer Ingelheim, Lilly, Pfizer, Novartis, Merck Sharp & Dohme, Chugai Pharmaceutical Co., Takeda, Citlone Pharmaceuticals, Janssen, TTY Biopharm, Orient EuroPharma, Mundipharma, GSK, Lotus Pharmaceutical, Onc Pharmaceutical, and Bristol Myers Squibb; received support for attending meetings and/or travel from AstraZeneca, Roche, and Chugai Pharmaceutical Co.; participated on a data safety monitoring board or advisory board for Takeda; and received grants or contracts from Roche and Genconn Biotech. **CM** served in a consulting or advisory role for AstraZeneca, Roche, Merck Sharp & Dohme, Sanofi, Pfizer, Takeda, Janssen, and Amgen; received payment or honoraria from AstraZeneca, Roche, Merck Sharp & Dohme, Amgen, Pfizer, Takeda, Bristol Myers Squibb, and Sanofi; and received support for attending meetings and/or travel for Janssen, Merck Sharp & Dohme, Takeda, Bristol Myers Squibb, Novartis, and Amgen. **UBR** served in a consulting or advisory role for Janssen. **JZ** received grants or contracts from AstraZeneca, Roche, and Bristol Myers Squibb; served in a consulting or advisory role for Bristol Myers Squibb, Sanofi, and Pfizer; received payment or honoraria from Janssen, Takeda, Sanofi, Roche, AstraZeneca, NanoString, Amgen, Bristol Myers Squibb, Pfizer, Merck Sharp & Dohme, and Diagnóstica Longwood; and received support for attending meetings and/or travel from Janssen, Sanofi, AstraZeneca, Takeda, and Roche. **C-HC** received payment or honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical Co., Daiichi Sankyo, Lilly, Janssen, Merck KGaA, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, Roche, Shionogi, and Takeda; participated on a data safety monitoring board or advisory board for AstraZeneca, Bristol Myers Squibb, Lilly, Janssen, Merck KGaA, Novartis, Ono Pharmaceutical, and Roche. **EN** served in a consulting or advisory role for Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Sanofi, Pfizer, Lilly, Amgen, Janssen, Daiichi Sankyo, Boehringer Ingelheim, AstraZeneca, Takeda, Sanofi, Pierre Fabre, and QIAGEN; received grants of contracts from Roche, Bristol Myers Squibb, and Pfizer; received payment or honoraria from Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Merck Serono, Sanofi, Pfizer, Lilly, Amgen, Janssen, Daiichi Sankyo, Boehringer Ingelheim, AstraZeneca, Takeda, Sanofi, Pierre Fabre, QIAGEN, and Bayer; received support for attending meetings and/or travel from Johnson & Johnson, Merck Sharp & Dohme, Takeda, and Roche; participated on a data safety monitoring board or advisory board for Roche, Appollonico, Merck Sharp & Dohme, and Transgene; and served in a leadership role for the Steering Committee of the Spanish Group of Lung Cancer (GECP). **HS-B** served in a consulting or advisory role for Johnson & Johnson, Lilly, and Boehringer Ingelheim; received payment or honoraria from Johnson & Johnson, Amgen, AstraZeneca, Merck Sharp & Dohme, and Takeda; received support for attending meetings and/or travel from Johnson & Johnson, Merck Sharp & Dohme, Dalichi Sankyo, and Sanofi. **PM, BGA, KX, GW, JME, MC, and JS** are employees and shareholders of Johnson & Johnson. **GL** served in a consulting or advisory role for Pfizer and AstraZeneca; owns stock or has other ownership interests with Lucence, Kills, BioMids, Morphometrix, and CDR-Life; received payment or honoraria from Boehringer Ingelheim, Blueprint Medicines, AstraZeneca, Merck, and Janssen; received research funding from AstraZeneca, Lucence, Kills, E.R. Squibb & Sons, Merck Sharp & Dohme, EMD Serono, AstraZeneca, Blueprint Medicines, Tesaro, Bavarian Nordic, Novartis, GI Therapeutics, Adaptimmune, Bristol Myers Squibb, GSK, Alaxia, Regeni, Pfizer, Roche, Genentech, Lilly, and Janssen; received support for attending meetings and/or travel from Boehringer Ingelheim, Pfizer, E.R. Squibb & Sons, Janssen, Celgene, Bsen, Pharmacyclics, Merck, AstraZeneca, and Seagen; and has other relationships with Mirati Therapeutics. **YJK** and **S-WK** have no conflicts of interest to disclose.

Background

- Amivantamab is an epidermal growth factor receptor (EGFR)–MET bispecific antibody with immune cell–directing activity[1–4]
- IV amivantamab is now FDA-approved in combination with lazertinib for the first-line treatment of non-small cell lung cancer (NSCLC) with common *EGFR* mutations, is EMA-approved with chemotherapy for second-line treatment of disease with common *EGFR* mutations after progression on osimertinib, and is FDA- and EMA-approved with chemotherapy for first-line treatment of NSCLC with *EGFR* exon 20 insertion mutations[4,5]
- Like many other IV therapies, IV amivantamab is associated with an increased rate of IRRs[6]
  - Approaches to manage IV amivantamab IRRs in other clinical trials included a split first dose over 2 days and premedication with antihistamines, antipyretics, and glucocorticoids
- In the phase 2 SKIPPirr (ClinicalTrials.gov Identifier: NCT05663866) study, additional prophylactic strategies to reduce the incidence and severity of IRRs with IV amivantamab were evaluated[7]
  - Prophylaxis with oral dexamethasone 8 mg BID for 2 days before infusion and another dose 1 hour before infusion (5 total doses) led to a ~3-fold reduction in IRRs from IV amivantamab (**Figure 1**)
- Here we present secondary endpoints and additional safety data from SKIPPirr

Figure 1: Primary results from SKIPPirr.[7] (A) Prophylactic schedule for dexamethasone 8 mg and (B) incidence of IRRs on C1D1



Clinical cutoff: C1D2.
[a]Includes standard premedications (antihistamines, antipyretics, and glucocorticoids).
C, Cycle; D, Day; dex, dexamethasone; EMA, European Medicines Agency; FDA, Food and Drug Administration; IRR, infusion-related reaction; IV, intravenous.

Methods

- SKIPPirr is a phase 2 study that evaluated additional prophylactic strategies to reduce the incidence and severity of IRRs with IV amivantamab (**Figure 2**)
- The study enrolled patients with *EGFR* exon 19 deletion or L858R-mutated advanced or metastatic NSCLC whose disease progressed on prior osimertinib and platinum-based chemotherapy
- All patients received IV amivantamab 1050 mg (1400 mg if ≥80 kg) once weekly for 4 weeks and then every 2 weeks thereafter, and oral lazertinib 240 mg once daily
- All patients also received standard IRR management with antihistamines, antipyretics, and IV dexamethasone 10 mg
- A Simon's 2-stage design with an expansion stage was used to evaluate 4 independent prophylactic strategies
- Only the dexamethasone 8 mg cohort passed stages 1 and 2 (2/6 and 6/16 patients with IRRs, respectively), enrolling an additional 24 patients

Figure 2: SKIPPirr study design



Clinical cutoff: 24 June 2024.
[a]Patients were sequentially enrolled into prophylactic regimens, with the dexamethasone 8 mg cohort enrolling last. Patients in all cohorts also received standard premedication with antihistamines, antipyretics, and glucocorticoids.
[b]If both cohorts had positive results, only 1 cohort moved on to stage 2, as determined by the SET.
[c]1 patient did not receive amivantamab infusion as scheduled on C1D1 per protocol and was excluded from the primary endpoint analysis.
[d]Defined as IRR events with onset within 24 hours of the start of the C1D1 amivantamab infusion and prior to the start of the C1D2 infusion.
AE, adverse event; BID, twice daily; C, Cycle; D, Day; IRR, infusion-related reaction; IV, intravenous; ORR, objective response rate; pt, patient; QD, once daily; SC, subcutaneous; SET, study evaluation team.

Results

Demographic and baseline characteristics

- Demographic and baseline characteristics were well balanced between the dexamethasone 8 mg cohort and the overall population (**Table 1**)

Table 1: Demographic and baseline characteristics

Characteristic	Dexamethasone 8 mg (n=41)	All cohorts (N=68)
Median age (range), years	62 (32–82)	63.5 (32–82)
Female, n (%)	26 (63)	44 (65)
Race, n (%)		
Asian	24 (59)	42 (62)
White	10 (24)	18 (26)
Black or African American	1 (2)	1 (1)
Not reported	6 (15)	7 (10)
ECOG PS score of 1, n (%)	32 (78)	51 (75)
Brain metastases, n (%)	15 (37)	30 (44)
EGFR mutation type, n (%)		
Exon 19 deletion	29 (71)	45 (66)
Exon 21 L858R	12 (29)	23 (34)
Median prior lines of therapy (range)	3 (2–9)	3 (2–9)

ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor.

IRRs through the end of Cycle 3

- In the dexamethasone 8 mg cohort, 10/41 (24%) patients experienced IRRs
  - 9 patients had IRRs on C1D1 (with 1 also on C1D2); 1 patient had an IRR on C2D1
  - All IRRs up to C3 were grades 1 or 2, except for one grade 3 IRR on C2D1

Safety

- Aside from the significantly reduced rate of IRRs, the safety profile of IV amivantamab + lazertinib was consistent with previous reports, with no new safety signals identified (**Table 2**)
- Common AEs associated with steroids (eg, fractures, Cushingoid features, and hyperglycemia)[8] were not observed in the dexamethasone 8 mg cohort
- Prophylaxis-related AEs occurred in 3 (7%) patients receiving dexamethasone 8 mg (1 event each of gastroesophageal reflux disease, muscle atrophy, and somnolence) and were all grades 1 or 2

Table 2: Safety profile

Most common treatment-emergent AEs (≥15%), n (%)	Dexamethasone 8 mg (n=41)		All cohorts (N=68)	
	Any grade	Grade ≥3	Any grade	Grade ≥3
Associated with EGFR inhibition				
Rash	17 (41)	0	30 (44)	4 (6)
Paronychia	16 (39)	0	30 (44)	0
Stomatitis	14 (34)	1 (2)	20 (29)	1 (1)
Pruritus	5 (12)	0	14 (21)	1 (1)
Dermatitis acneiform	7 (17)	0	12 (18)	0
Diarrhea	7 (17)	1 (2)	12 (18)	1 (1)
Associated with MET inhibition				
Hypoalbuminemia	17 (41)	0	24 (35)	1 (1)
Peripheral edema	9 (22)	0	14 (21)	0
Other				
IRR	10 (24)	1 (2)	31 (46)	2 (3)
Nausea	10 (24)	1 (2)	22 (32)	2 (3)
Epistaxis	9 (22)	0	13 (19)	0
Dyspnea	8 (20)	1 (2)	11 (16)	2 (3)
Hypoesthesia	8 (20)	0	14 (21)	0
Headache	8 (20)	0	10 (15)	0
Constipation	8 (20)	0	12 (18)	0
Hypotension	8 (20)	2 (5)	9 (13)	2 (3)
Asthenia	7 (17)	2 (5)	12 (18)	3 (4)
Dry skin	6 (15)	0	10 (15)	1 (1)
Pain in extremity	5 (12)	0	10 (15)	0
Decreased appetite	4 (10)	0	11 (16)	2 (3)
Chills	0	0	10 (15)	0

AE, adverse event; EGFR, epidermal growth factor receptor; IRR, infusion-related reaction.

Efficacy

- The investigator-assessed objective response rate among all responders and confirmed responders in the dexamethasone 8 mg cohort was similar to historic IV amivantamab data from CHRYSALIS-2 Cohort A and PALOMA-3 (**Table 3**)[9–11]

Table 3: Response by investigator

Investigator-assessed response	SKIPPirr: dexamethasone 8 mg IRR prophylaxis (n=40)[a]	CHRYSALIS-2: Cohort A[1,3] (n=162)	PALOMA-3: IV arm[2] (n=212)
ORR, % (95% CI)			
All responders	33 (19–49)	33 (26–41)	33 (26–39)
Confirmed responders	28 (15–44)	28 (22–36)	27 (21–33)
Best response, n (%)[b]			
CR	0	1 (0.6)	1 (0.5)
PR	11 (28)	45 (28)	68 (32)
SD	16 (40)	79 (49)	81 (38)
Non-CR/non-PD	2 (5)	–	–
PD	10 (25)	34 (21)	42 (20)
NE/unknown	1 (3)	3 (2)	20 (9)
CBR, % (95% CI)	73 (56–85)[c]	58 (50–66)[c]	71 (64–77)[d]

[a]1 patient did not receive amivantamab infusion as scheduled on C1D1 per protocol and was excluded from this analysis.
[b]Among confirmed responders, except for PALOMA-3, which shows all responders.
[c]CBR is defined as the percentage of patients with CR, PR, SD, or non-CR/non-PD (SKIPPirr) or the percentage of patients with CR, PR, or durable SD (≥11 weeks; CHRYSALIS-2 Cohort A).
[d]Not protocol specified. Calculated as the sum of CR, PR, and SD; all responders were included.
C, cycle; CBR, clinical benefit rate; CI, confidence interval; CR, complete response; D, day; IRR, infusion-related reaction; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.

Duration of amivantamab infusion

- At C1D1, the median amivantamab infusion time was numerically shorter for the dexamethasone 8 mg cohort versus the other cohorts combined (4.4 hours vs 5.2 hours; **Figure 3**)
- By C1D15 and onward, the median duration of amivantamab infusion was approximately 2.3 hours for all cohorts, which was consistent with the low IRR incidence after C1D1 and increased infusion rate over time

Figure 3: Duration of amivantamab infusion



Note: Duration of infusion includes both actual infusion time and interruption time, if any. Patients who aborted infusions due to AEs and those with an infusion end time recorded incorrectly were excluded.
[a]Includes the dexamethasone 4 mg, montelukast, and methotrexate cohorts.
AE, adverse event.

Time and motion on C1D1

- On C1D1, patients receiving dexamethasone 8 mg spent a numerically shorter amount of time in the treatment room and infusion chair and required a numerically shorter amount of active HCP time versus the other cohorts combined (**Figure 4**)

Figure 4: Time and motion on C1D1



Note: Patients who aborted infusions due to AEs and those who inadvertently excluded the line flush time from their infusion calculation were excluded.
[a]Includes the dexamethasone 4 mg, montelukast, and methotrexate cohorts.
AE, adverse event; C, Cycle; D, Day; HCP, health care provider.

References

1. Moores SL, et al. *Cancer Res*. 2016;76(13):3942–3953. 2. Vijayaraghavan S, et al. *Mol Cancer Ther*. 2020;19(10):2044–2056. 3. Yun J, et al. *Cancer Discov*. 2020;10(8):1194–1209. 4. RYBREVANT® (amivantamab-vmjw) injection for intravenous use [package insert]. Janssen Biotech, Inc.; 2024. 5. European Commission approves RYBREVANT® (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy. News release. Johnson & Johnson. August 27, 2024. 6. Park K, et al. *Lung Cancer*. 2023;178:166–171. 7. Lopes G, et al. Presented at: World Conference on Lung Cancer (WCLC); September 7–10, 2024; San Diego, CA, USA. 8. Hodgens A, et al. Corticosteroids. In: *StatPearls*. StatPearls Publishing; 2023. 9. Shu CA, et al. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3–7, 2022; Chicago, IL, USA. 10. Leighl NB, et al. *J Clin Oncol*. 2024. Online ahead of print. doi: 11.1200/JCO.24.01001. 11. Data on file.

Corresponding author: Luis Paz-Ares (luis.paz-ares@salud.madrid.org)

Lung Cancer

Presented by L Paz-Ares at the European Society for Medical Oncology (ESMO) Annual Meeting; September 13–17, 2024; Barcelona, Spain